- Home
- AKBA vs SEG Comparison
AKBA vs SEG Comparison
Compare AKBA & SEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- SEG
- Stock Information
- Founded
- AKBA 2007
- SEG 2024
- Country
- AKBA United States
- SEG United States
- Employees
- AKBA N/A
- SEG N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- SEG
- Sector
- AKBA Health Care
- SEG
- Exchange
- AKBA Nasdaq
- SEG NYSE
- Market Cap
- AKBA 336.2M
- SEG 343.2M
- IPO Year
- AKBA 2014
- SEG N/A
- Fundamental
- Price
- AKBA $2.37
- SEG $27.01
- Analyst Decision
- AKBA Strong Buy
- SEG
- Analyst Count
- AKBA 1
- SEG 0
- Target Price
- AKBA $7.50
- SEG N/A
- AVG Volume (30 Days)
- AKBA 2.4M
- SEG 78.8K
- Earning Date
- AKBA 03-13-2025
- SEG 02-05-2025
- Dividend Yield
- AKBA N/A
- SEG N/A
- EPS Growth
- AKBA N/A
- SEG N/A
- EPS
- AKBA N/A
- SEG N/A
- Revenue
- AKBA $169,879,000.00
- SEG $111,487,000.00
- Revenue This Year
- AKBA N/A
- SEG N/A
- Revenue Next Year
- AKBA $30.85
- SEG N/A
- P/E Ratio
- AKBA N/A
- SEG N/A
- Revenue Growth
- AKBA N/A
- SEG 36.09
- 52 Week Low
- AKBA $0.80
- SEG $23.26
- 52 Week High
- AKBA $2.48
- SEG $36.50
- Technical
- Relative Strength Index (RSI)
- AKBA 75.15
- SEG N/A
- Support Level
- AKBA $1.72
- SEG N/A
- Resistance Level
- AKBA $2.00
- SEG N/A
- Average True Range (ATR)
- AKBA 0.11
- SEG 0.00
- MACD
- AKBA 0.04
- SEG 0.00
- Stochastic Oscillator
- AKBA 100.00
- SEG 0.00
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About SEG SEAPORT ENTERTAINMENT GROUP INC
Seaport Entertainment Group Inc own, operate and develop a unique collection of assets positioned at the intersection of entertainment and real estate. Its objective is to integrate one-of-a-kind real estate assets with a variety of restaurant, retail and leisure offerings to form vibrant mixed-use destinations where customers can work, play and socialize in one cohesive setting. The company has three operating segments: (1) Landlord Operations; (2) Hospitality; and (3) Sponsorships, Events, and Entertainment. Key revenue is generated from Landlord Operations which consists of the company's rental operations.